EarlyNarratives
Pricing
Start free trialSign in
Daily Briefing

Daily briefings with evidence trails.

We de-duplicate the flood, cluster it into Signals (topics), and connect them into Storylines (narratives) — with every claim traceable to sources.

Signals = topics • Storylines = narratives across days

Evidence-linked signals
Read today’s briefingGet email briefings
Methodology
Example signal
Free sample

Novo’s Next-Gen Obesity Shot Fails to Match Lilly Drug in Head-to-Head Study

Novo Nordisk's CagriSema has failed to outperform Eli Lilly's Zepbound in a critical phase 3 weight loss study, resulting in a significant drop in the company's stock...

Why now: The results from the phase 3 trial were released recently, prompting immediate market reactions.

Full evidence trail included.
Open today's flagship sampleRead today's briefingExplore signals
Start with today’s briefing

Scan the output first - drill into Signals when something matters.

Signal

Advancements in Computational Methods for Protein Interactions

Recent studies highlight significant advancements in computational methods for protein interactions. G-LEAP, a deep learning framework, enhances the understanding of GPCR-ligand interactions, achieving superior generalization.

Why now: Recent breakthroughs in deep learning are transforming drug discovery.

CurrentSource diversity aware
Evidence: 3 sources
See details ->
Signal

Innovative Approaches to Epilepsy Management: Connectivity and Gut Microbiome Insights

Recent research highlights two promising approaches to epilepsy management: one focusing on brain connectivity and the other on gut microbiome modulation through vagus nerve stimulation. These studies could lead to new therapeutic strategies for drug-resistant epilepsy.

Why now: These studies provide timely insights as epilepsy remains a significant global health issue.

CurrentSource diversity aware
Evidence: 2 sources
See details ->
Signal

New Insights into Influenza Vaccine Efficacy and Antibody Responses

Recent studies investigate the immune response to influenza vaccines, focusing on the effectiveness of egg-derived versus recombinant protein vaccines against new H1N1 strains and the role of non-neutralizing antibodies in mitigating disease symptoms.

Why now: The 2023/2024 influenza season is approaching, necessitating effective vaccine strategies.

CurrentSource diversity aware
Evidence: 2 sources
See details ->
Product tour

A short walkthrough of the BIOTECH dashboards.

Product tour

A short walkthrough of the BIOTECH dashboards.

How it works

Evidence-first, transparent, and tuned to reduce amplification noise.

Ingest broadly

News, social, dev, and primary sources.

De-duplicate

Remove rewrites, SEO clones, and engagement spam.

Score evidence

Reward independent confirmation and source diversity.

Ship outputs

Signals -> Storylines -> Briefings (evidence-linked, traceable).

See Methodology
Why EarlyNarratives exists

We are living through an information regime change. Feeds are flooded with duplication, SEO rewrites, and engagement-driven noise. When everything looks urgent, clarity breaks down.

EarlyNarratives is the calm layer: we ingest broadly, strip duplicates, score evidence, and surface Signals, then connect them into Storylines across days and weeks.

What you get
Signals

A ranked view of the strongest signals with evidence snapshots.

Storylines

Continuity across days and weeks, not just today’s spike.

Weekly Briefing

A concise briefing of Storylines plus notable one-off signals.

Evidence-linked by defaultSource-diversity aware
Explore Signals
See pricingWeekly Briefing